Frataxin gene promoter (FXN promoter) (FXN promoter)

The Frataxin (FXN) gene promoter and its associated CpG-rich regulatory DNA are essential components for the transcriptional regulation of the frataxin protein, which plays a vital role in mitochondrial iron-sulfur cluster assembly (PMID: 8599158). In patients with Friedreich's Ataxia (FRDA), a GAA triplet repeat expansion within the first intron of the FXN gene induces a heterochromatic state characterized by DNA hypermethylation and histone deacetylation at the promoter and surrounding regulatory regions (PMID: 17434992). This epigenetic silencing leads to a significant reduction in FXN mRNA and protein levels, resulting in mitochondrial dysfunction and progressive neurodegeneration (PMID: 17172454). Therapeutic strategies targeting this region focus on reactivating the silenced gene through the use of small molecule histone deacetylase (HDAC) inhibitors, DNA methyltransferase inhibitors, or synthetic transcription factors designed to bind the promoter and initiate transcription (PMID: 23892737, PMID: 25431144). Monitoring the methylation status and histone acetylation levels of this regulatory DNA serves as a critical biomarker for evaluating the efficacy of these epigenetic-based therapies.

Other names

FXN regulatory DNAFrataxin 5' regulatory regionFXN CpG islandFXN 5' UTR regulatory element

The primary mechanism of action involves the reversal of epigenetic silencing through the inhibition of histone deacetylases (HDACs) or DNA methyltransferases, thereby promoting a transition from heterochromatin to euchromatin at the FXN locus. Additionally, synthetic transcription factors and CRISPR-based activators (CRISPRa) can be recruited to the promoter to directly stimulate the transcriptional machinery and bypass the repressive effects of the GAA expansion.